{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"indomethacin-embryofetopathy","columns":[{"gene":"","key":"population-a4e2693bfff26e00d842","label":"Indomethacin embryofetopathy","mondoId":"MONDO:0016005","onsetQualifier":null,"originColumnKey":"MONDO:0016005/ORPHA:1909","originalViews":[{"key":"MONDO:0016005/ORPHA:1909","label":"Indomethacin embryofetopathy","scopeLabel":"ORPHA:1909","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["057d81341819f67e75fc910ef062a4efcef706bb58f456cf483b4fee2c29c8ff","0a571743af59ac9444d5e0180f23bd178f8a7ad95dc3e9a51247339c92a5cbaf","110e74586d963c5d2e299790712fff9bc68fd0207f4cd2e1ab6978079e020173","2887e55bc3aefaad8ca7dd6605d6089f0de10ba9195ddc96aa2c13b17523ecc4","47fcda93a5b94c8f2c6738b34b225848bb2d0fc55bfd9dc4d048ce54013bbf14","488ec764cbdd0b88945ef757cd82c5f8671235765bc7d1af8f5c00eb134863e8","59416326ef9f38f0a08a01941403083a883d39f61c6ed8ee3ac6c5d86d9bbbe8","5e2e793a52c966042b5dc6df3fbbaeec339f68005d9103aaf82f457c5aead320","73a8b191e2dcd7f69821e876f952d9de498ee07feadbc8e4e8ca6dbc62be9375","b036971c8cb0cec6b740c6cac35ea2079b9420fa618a23a0e9295ca3ecbe023b","e08f8b558cf4e70ae3c6a2876e46f50fbd9c3dee81d33cb7174402f84f42d4d3","feaa674ae6018390eb6741ffc7cd8a6a073f9a270eed3c627c9fa7646a3c6b34"],"recordQualifiers":{},"scopeLabel":"ORPHA:1909","sourceIds":["ORPHA:1909"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-a4e2693bfff26e00d842"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0000091","HP:0001928","HP:0001631","HP:0001638","HP:0001789","HP:0000003","HP:0000112"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":12,"sourceGroups":{"orphanet":12}},"features":[{"hpoId":"HP:0000091","label":"Abnormal renal tubule morphology","primary":true},{"hpoId":"HP:0001928","label":"Abnormality of coagulation","primary":true},{"hpoId":"HP:0001631","label":"Atrial septal defect","primary":true},{"hpoId":"HP:0001638","label":"Cardiomyopathy","primary":true},{"hpoId":"HP:0001789","label":"Hydrops fetalis","primary":true},{"hpoId":"HP:0000003","label":"Multicystic kidney dysplasia","primary":true},{"hpoId":"HP:0000112","label":"Nephropathy","primary":true},{"hpoId":"HP:0001562","label":"Oligohydramnios","primary":false},{"hpoId":"HP:0001622","label":"Premature birth","primary":false},{"hpoId":"HP:0000083","label":"Renal insufficiency","primary":false},{"hpoId":"HP:0002093","label":"Respiratory insufficiency","primary":false},{"hpoId":"HP:0001629","label":"Ventricular septal defect","primary":false}],"ledeHtml":"Indomethacin embryofetopathy refers to the manifestations that may be observed in a fetus or newborn when the mother has taken indomethacin, a potent prostaglandin inhibitor and tocolytic agent that can cross placenta, during pregnancy. Reported adverse fetal/neonatal effects include decreased renal function resulting in oligohydramnios, closure of the ductus arteriosus, and delayed cardiovascular adaptation at birth. These effects are usually transient and reversible. Indomethacin may also be a risk factor for cerebral injury (periventricular leukomalacia) and necrotizing enterocolitisin preterm infants.","mondoId":"MONDO:0016005","node":{"canonicalSlug":"indomethacin-embryofetopathy","comparisons":[{"documentSha256":"3ae02ede64837bdd5aa6808291399823ab2fde00cc3f2e3be1195228dc83acd2","key":"legacy-indomethacin-embryofetopathy","kind":"legacy","label":"indomethacin embryofetopathy","memberIds":["MONDO:0016005"],"mondoId":"MONDO:0016005","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/indomethacin-embryofetopathy.3ae02ede64837bdd5aa6808291399823ab2fde00cc3f2e3be1195228dc83acd2.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","matchMethod":"same-ontology-node","name":"indomethacin embryofetopathy","paragraphs":["Indomethacin embryofetopathy refers to the manifestations that may be observed in a fetus or newborn when the mother has taken indomethacin, a potent prostaglandin inhibitor and tocolytic agent that can cross placenta, during pregnancy. Reported adverse fetal/neonatal effects include decreased renal function resulting in oligohydramnios, closure of the ductus arteriosus, and delayed cardiovascular adaptation at birth. These effects are usually transient and reversible. Indomethacin may also be a risk factor for cerebral injury (periventricular leukomalacia) and necrotizing enterocolitisin preterm infants."],"scope":"exact","source":"MONDO","upstream":"Orphanet:1909","url":"https://monarchinitiative.org/MONDO:0016005"},"ownColumnKeys":["population-a4e2693bfff26e00d842"],"publication":"published","relationships":[{"kind":"parent","label":"toxic or drug-related embryofetopathy","mondoId":"MONDO:0016677","slug":null}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"range","key":"057d81341819f67e75fc910ef062a4efcef706bb58f456cf483b4fee2c29c8ff","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:1909","disease_name":"Indomethacin embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001638","is_excluded":false,"label":"Cardiomyopathy","onset_id":null,"reference":"ORPHA:1909","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"0a571743af59ac9444d5e0180f23bd178f8a7ad95dc3e9a51247339c92a5cbaf","raw":{"aspect":"P","body_system":"prenatal","disease_id":"ORPHA:1909","disease_name":"Indomethacin embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001789","is_excluded":false,"label":"Hydrops fetalis","onset_id":null,"reference":"ORPHA:1909","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"110e74586d963c5d2e299790712fff9bc68fd0207f4cd2e1ab6978079e020173","raw":{"aspect":"P","body_system":"prenatal","disease_id":"ORPHA:1909","disease_name":"Indomethacin embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001562","is_excluded":false,"label":"Oligohydramnios","onset_id":null,"reference":"ORPHA:1909","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"2887e55bc3aefaad8ca7dd6605d6089f0de10ba9195ddc96aa2c13b17523ecc4","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:1909","disease_name":"Indomethacin embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000112","is_excluded":false,"label":"Nephropathy","onset_id":null,"reference":"ORPHA:1909","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"47fcda93a5b94c8f2c6738b34b225848bb2d0fc55bfd9dc4d048ce54013bbf14","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:1909","disease_name":"Indomethacin embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000003","is_excluded":false,"label":"Multicystic kidney dysplasia","onset_id":null,"reference":"ORPHA:1909","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"488ec764cbdd0b88945ef757cd82c5f8671235765bc7d1af8f5c00eb134863e8","raw":{"aspect":"P","body_system":"prenatal","disease_id":"ORPHA:1909","disease_name":"Indomethacin embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001622","is_excluded":false,"label":"Premature birth","onset_id":null,"reference":"ORPHA:1909","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"59416326ef9f38f0a08a01941403083a883d39f61c6ed8ee3ac6c5d86d9bbbe8","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:1909","disease_name":"Indomethacin embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001928","is_excluded":false,"label":"Abnormality of coagulation","onset_id":null,"reference":"ORPHA:1909","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"5e2e793a52c966042b5dc6df3fbbaeec339f68005d9103aaf82f457c5aead320","raw":{"aspect":"P","body_system":"respiratory","disease_id":"ORPHA:1909","disease_name":"Indomethacin embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0002093","is_excluded":false,"label":"Respiratory insufficiency","onset_id":null,"reference":"ORPHA:1909","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"73a8b191e2dcd7f69821e876f952d9de498ee07feadbc8e4e8ca6dbc62be9375","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:1909","disease_name":"Indomethacin embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001629","is_excluded":false,"label":"Ventricular septal defect","onset_id":null,"reference":"ORPHA:1909","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"b036971c8cb0cec6b740c6cac35ea2079b9420fa618a23a0e9295ca3ecbe023b","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:1909","disease_name":"Indomethacin embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000083","is_excluded":false,"label":"Renal insufficiency","onset_id":null,"reference":"ORPHA:1909","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"e08f8b558cf4e70ae3c6a2876e46f50fbd9c3dee81d33cb7174402f84f42d4d3","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"ORPHA:1909","disease_name":"Indomethacin embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000091","is_excluded":false,"label":"Abnormal renal tubule morphology","onset_id":null,"reference":"ORPHA:1909","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"feaa674ae6018390eb6741ffc7cd8a6a073f9a270eed3c627c9fa7646a3c6b34","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:1909","disease_name":"Indomethacin embryofetopathy","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001631","is_excluded":false,"label":"Atrial septal defect","onset_id":null,"reference":"ORPHA:1909","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0016005\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>same-ontology-node</dd><dt>Upstream attribution</dt><dd>Orphanet:1909</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Indomethacin embryofetopathy refers to the manifestations that may be observed in a fetus or newborn when the mother has taken indomethacin, a potent prostaglandin inhibitor and tocolytic agent that can cross placenta, during pregnancy. Reported adverse fetal/neonatal effects include decreased renal function resulting in oligohydramnios, closure of the ductus arteriosus, and delayed cardiovascular adaptation at birth. These effects are usually transient and reversible. Indomethacin may also be a risk factor for cerebral injury (periventricular leukomalacia) and necrotizing enterocolitisin preterm infants.</p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0016005\" rel=\"noreferrer\">MONDO</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"indomethacin-embryofetopathy","sourceDocuments":[{"name":"MONDO: indomethacin embryofetopathy","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0016005"}],"sourceNote":"","synonyms":["antenatal indomethacin exposure","fetal indomethacin syndrome","foetal indomethacin syndrome"],"takeawayHtml":"","title":"indomethacin embryofetopathy"},"schemaVersion":1}
